Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds ...
CRISPR Therapeutics (SRSP) stock gains as the company gets a new Overweight rating from J.P. Morgan thanks to its therapeutic ...
CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best emerging technology stocks to buy right now. On September 3, Bank of ...
While the telephone brought comfort, smartphones changed lives. While factories powered economies, artificial intelligence ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...
Cathie Wood is known for seizing opportunities. The founder of Ark Invest doesn't worry when one of the stocks she's invested ...
CRISPR Therapeutics AG ( NASDAQ: CRSP) H.C. Wainwright 27th Annual Global Investment Conference September 8, 2025 4:30 PM EDT ...
The 12-month price targets, analyzed by analysts, offer insights with an average target of $5.0, a high estimate of $6.00, and a low estimate of $4.00. Witnessing a positive shift, the current average ...
DAVIS, CALIF. — Scientists at the University of California, Davis, have developed wheat plants that stimulate production of its own fertilizer, which could bring environmental and cost-reduction ...
Marvell Technologies stock tumbled on Friday after a disappointing earnings report. The company reported light data-center revenue, and its sales forecast missed estimates. Analysts are worried that ...
CRISPR Therapeutics is the first company to secure an FDA approval of a gene-editing drug. That drug's underlying science, however, could be used to create treatments for any number of genetically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results